Angiotensin I (human, mouse, rat): Precursor Peptide for Renin-Angiotensin System Research

Executive Summary: Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) is a decapeptide generated by renin cleavage of angiotensinogen, serving as the direct precursor to angiotensin II, a potent vasoconstrictor (APExBIO). The conversion of Angiotensin I to Ang II by angiotensin-converting enzyme (ACE) is essential for regulating blood pressure and vascular tone (Angiotensin II site). Angiotensin I itself is biologically inactive, but is critical for mechanistic studies of the renin-angiotensin system and is widely used to screen antihypertensive drugs. Solubility, storage, and handling parameters are well-characterized, supporting its robust use in both in vitro and in vivo research models. Intracerebroventricular administration in animals demonstrates its value in neuroendocrine and cardiovascular pathway elucidation (Adrenomedullin site).

Biological Rationale

Angiotensin I is a decapeptide with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, conserved across human, mouse, and rat species (APExBIO). It is produced when renin cleaves angiotensinogen, a circulating glycoprotein synthesized in the liver (Scenario Solutions). This process is the rate-limiting step in the renin-angiotensin system, a major regulator of blood pressure, electrolyte balance, and fluid homeostasis. Angiotensin I has no significant direct biological activity, but its downstream conversion to angiotensin II is central to vasoconstriction and aldosterone release. The stability and defined structure of Angiotensin I make it a reliable standard in experimental workflows.

Mechanism of Action of Angiotensin I (human, mouse, rat)

Angiotensin I itself is not directly active on known cellular receptors. It acts as the immediate precursor to angiotensin II, generated by the removal of two C-terminal amino acids via ACE (Molecular Gateway). Angiotensin II binds Gq protein-coupled receptors, particularly the AT1 subtype on vascular smooth muscle cells. This binding triggers phospholipase C activation, leading to inositol trisphosphate (IP3) generation and subsequent intracellular calcium release. The result is rapid vasoconstriction and increased systemic blood pressure. Angiotensin I is therefore indispensable in dissecting the enzymatic and signaling components of the renin-angiotensin cascade. Researchers employ Angiotensin I to precisely time and quantify the conversion to Ang II, especially in the presence or absence of ACE inhibitors.

Evidence & Benchmarks

• Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) is a decapeptide with a molecular weight of 1296.5 Da (APExBIO).
• Renin cleaves angiotensinogen to generate Angiotensin I, the rate-limiting step in the renin-angiotensin system (Angiotensin II site).
• Angiotensin I is biologically inactive until converted to Ang II by ACE (Scenario Solutions).
• Angiotensin II activates Gq-coupled AT1 receptors, leading to IP3-dependent intracellular signaling and vasoconstriction (Molecular Gateway).
• Angiotensin I is soluble in DMSO (≥129.6 mg/mL), water (≥124.2 mg/mL), and ethanol (≥9.16 mg/mL) (APExBIO).
• Intracerebroventricular injection of Angiotensin I increases fetal blood pressure and activates AVP neurons in animal models (Adrenomedullin site).
• Peptide should be stored desiccated at -20°C and shipped on blue ice to preserve activity (APExBIO).
• Angiotensin I is a reference compound for antihypertensive drug screening assays (Applied Tools).

Applications, Limits & Misconceptions

Angiotensin I is widely used in basic and applied research to model the renin-angiotensin system, dissect cardiovascular disease mechanisms, and screen ACE inhibitors and other antihypertensive agents (APExBIO). It is employed in both in vitro enzymatic assays and in vivo animal studies, including intracerebroventricular injection protocols to probe neuroendocrine responses. Its defined structure allows for reproducible experimental design and data interpretation.

For extended context, the article "Optimizing RAS Assays: Scenario Solutions with Angiotensin I (human, mouse, rat)" focuses on troubleshooting and protocol optimization, while this article provides a detailed molecular and mechanistic overview supporting those workflows. Additionally, "Angiotensin I (human, mouse, rat): Molecular Precursor in..." outlines the atomic sequence and experimental roles, which are further detailed here regarding solubility and storage for rigorous laboratory use.

Common Pitfalls or Misconceptions

• Angiotensin I does not directly induce vasoconstriction; only Angiotensin II is biologically active in this pathway.
• Peptide degradation can occur if not stored desiccated at -20°C or if repeatedly thawed and refrozen.
• Assay artifacts may arise if impurities or improper solvents are used; always verify peptide identity via mass spectrometry.
• Species differences in ACE or receptor expression may affect in vivo response profiles.
• Angiotensin I is not a substitute for Ang II in direct receptor activation studies.

Workflow Integration & Parameters

For experimental applications, Angiotensin I (SKU A1006) is supplied as a solid, with high solubility in DMSO (≥129.6 mg/mL), water (≥124.2 mg/mL), and ethanol (≥9.16 mg/mL) (APExBIO). The recommended storage conditions are -20°C in a desiccated environment to prevent hydrolysis and oxidation. Aliquots should be prepared to minimize freeze-thaw cycles. The compound is shipped on blue ice to maintain peptide integrity. For in vivo applications, such as intracerebroventricular injection, dosing and vehicle selection should be matched to species and end-point measurements. Angiotensin I can be used in enzymatic assays to monitor ACE activity, or in pharmacological screens for antihypertensive drug efficacy. When designing cardiovascular or neuroendocrine experiments, it is critical to control for peptide purity and solvent effects.

Conclusion & Outlook

Angiotensin I (human, mouse, rat) is a rigorously defined tool for renin-angiotensin system research, offering atomic precision in cardiovascular, neuroendocrine, and pharmacological studies. Its specificity as an enzymatic precursor to Ang II underpins its central role in mechanistic assays and drug screening platforms. As new therapeutic targets emerge within the renin-angiotensin cascade, Angiotensin I will remain essential for validating pathway interventions and benchmarking assay performance. For detailed product specifications and ordering, refer to the APExBIO Angiotensin I (human, mouse, rat) product page.